Integrated Research Associates

Executive Summary

Integrated Research Associates (IRA) is a privately held biotechnology company based in Marin County, California, focused on developing vaccines and therapeutics for emerging viral diseases with significant public health impact. Founded in 2007, IRA targets dengue, Zika, Japanese encephalitis, and enteroviruses 68 and 71. The company also generates recurring revenue by selling inactivated viral antigens and monoclonal antibodies for diagnostic and research use, providing a financial buffer typical of early-stage firms. While IRA has not disclosed funding rounds or valuation, its long operational history suggests resilience and a lean, focused R&D model. IRA's platform technologies could address unmet needs in flavivirus and enterovirus prevention, particularly in pediatric and travel medicine markets. However, as a small private entity, the company faces challenges in scaling clinical development without a clear partner or significant capital infusion. The absence of publicly disclosed pipeline candidates or trial status limits visibility. Nonetheless, IRA's revenue from reagent sales and its niche positioning in multiple viral targets offer potential for partnerships or licensing deals. Given the limited public information, the conviction score is moderate, reflecting both the inherent uncertainty of private biotech and the plausible value in its specialized product offerings.

Upcoming Catalysts (preview)

• Q4 2026Enterovirus D71 vaccine preclinical results or Investigational New Drug (IND) filing30% success
• TBDPartnership or licensing deal for dengue or Zika vaccine candidate25% success
• Q3 2026Expansion of diagnostic reagent product line or new customer contract60% success